Hypothesis Aging tissues accumulate senescent cells that package specific microRNAs into extracellular vesicles (EVs). These EVs are taken up by neighboring parenchymal cells and deliver miR‑34a, which directly binds the 3′‑UTR of ULK1 mRNA, suppressing its translation. Reduced ULK1 protein diminishes the initiating kinase complex for autophagy, leading to the observed stall in autophagic flux. Because EV‑mediated transfer is reversible, restoring autophagy in old age may require blocking EV release or neutralizing miR‑34a, rather than replacing core autophagy proteins.

Mechanistic Basis Senescent cells exhibit a persistent mTORC1 signal that drives both autophagy for their own survival and the secretion of a pro‑inflammatory SASP. Recent work shows that SASP includes lipid‑rich EVs enriched in certain miRNAs. In vitro, miR‑34a levels rise with replicative senescence and can inhibit ULK1 expression in muscle progenitors. The age‑dependent increase in RUBCN and decline in NRF2 described earlier would synergize with miR‑34a‑mediated ULK1 repression: RUBCN limits PI3P production, NRF2 loss lowers basal autophagy gene expression, and EV‑delivered miR‑34a hits the upstream initiator. Together, these layers create a robust blockade that is regulatory, not structural.

Predictions

1. Isolates of EVs from old mouse serum will contain higher miR‑34a than those from young mice, and EV‑mediated transfer to cultured myotubes will decrease ULK1 protein and LC3‑II conversion.
2. Pharmacological inhibition of neutral sphingomyelinase (GW4869) to block EV release in aged mice will restore ULK1 levels, increase autophagosome formation, and improve muscle strength without altering mTORC1 activity.
3. Antagomir‑based neutralization of miR‑34a in vivo will rescue autophagy flux in neurons of Alzheimer’s model mice, reducing p62 accumulation.
4. Genetic ablation of miR‑34a specifically in senescent cells (using p16‑CreER) will attenuate the paracrine suppression of autophagy in adjacent tissues.

Experimental Approach

• Collect serum from young (3 mo) and old (24 mo) C57BL/6 mice, isolate EVs by ultracentrifugation, quantify miR‑34a by qPCR.
• Treat primary human myotubes with EVs; measure ULK1 Western blot, phospho‑ULK1 (Ser555), and GFP‑LC3 puncta.
• In aged mice, administer GW4869 or scrambled control for 4 weeks; assess muscle autophagic flux (LC3‑II/I ratio with bafilomycin), grip strength, and histology.
• Use antagomir‑34a conjugated to a liver‑targeting ligand; evaluate neuronal autophagy in APP/PS1 mice via EM and p62 staining.
• Generate p16‑CreER; miR‑34a^fl/fl mice, induce senescence clearance, compare autophagic markers in muscle and brain.

Implications If validated, this hypothesis shifts the therapeutic focus from boosting autophagy machinery to intercepting paracrine RNA signals that actively suppress it. It explains why overexpression of WIPI2 or ATG5 rescues flux: they act downstream of the blocked initiation step. Moreover, it links the SASP, EV biology, and age‑related miRNA dysregulation into a unified mechanism that can be tested with existing tools.